CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Ion Beam Applications SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Ion Beam Applications SA
Chemin du Cyclotron 3
Phone: +32 10475811p:+32 10475811 LOUVAIN-LA-NEUVE, 1348  Belgium Ticker: IBABIBAB

Business Summary
Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/202212/31/2021Yes---Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Representing Saint-Denis SA PierreMottet 1/1/2013 1/1/1988
Chief Executive Officer, Managing Director, Inside Director OlivierLegrain 5/9/2012 5/9/2012
Chief Financial Officer, Member of the Management Board SoumyaChandramouli 1/1/2019 1/1/2016
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Modus Medical Devices Inc. 1570 N Routledge Park London ON Canada

Business Names
Business Name
0GZK
BetaPlus Pharma S.A.
Cis Bio GmbH
31 additional Business Names available in full report.

General Information
Number of Employees: 1,668 (As of 6/30/2022)
Outstanding Shares: 29,916,549 (As of 6/30/2022)
Shareholders: 66,649
Stock Exchange: EBR
Federal Tax Id: 541803305
Fax Number: +32 10475810


Copyright © 2022 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, October 7, 2022